Cantex Pharmaceuticals Competitors and Similar CompaniesClear all

Cantex Pharmaceuticals's competitors and similar companies include Nektar Therapeutics, Exelixis and Nykode Therapeutics.

	Cantex Pharmaceuticals Cantex Pharmaceuticals is a pharmaceutical company developing proprietary pharmaceuticals that improve the treatment of cancer.	Nektar Therapeutics Nektar Therapeutics is a stage-clinical biopharmaceutical company.	Exelixis Exelixis is an oncology company that develops cancer treatments.	Nykode Therapeutics Nykode Therapeutics (formerly known as Vaccibody) is a biopharmaceutical company dedicated to the discovery and development of immunotherapies.
Founding Date	Founding Date 2002	Founding Date 1990	Founding Date 1994	Founding Date 2007
Type	Type Private	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma
Locations	Locations Weston, US HQ	Locations San Francisco, US HQ Hyderabad, IN Huntsville, US	Locations Alameda, US HQ	Locations Oslo, NO HQ
Employees	Employees 650% increase	Employees 61821% increase	Employees 1,14712% decrease	Employees 135
Valuation ($)	Valuation ($) N/A	Valuation ($) 233.8 m	Valuation ($) 8.2 b	Valuation ($) 144.4 m
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $55.2m (FY, 2025)	Revenue (est.) $2.3b (FY, 2025)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods $83.7m (FY, 2025)	Cost of goods $1.3m (FY, 2025)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit $2.2b (FY, 2025)	Gross profit ($801k) (FY, 2025)
Net income	Net income N/A	Net income ($164.1m) (FY, 2025)	Net income $782.6m (FY, 2025)	Net income ($12.2m) (FY, 2025)
Funding
Total funding raised	Total funding raised $ 27.4m	Total funding raised $ 45m	Total funding raised N/A	Total funding raised $ 31.5m